System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Frédéric Dumont is an expert in Surgery at Institut de Cancérologie de l'Ouest (France). Frédéric Dumont has authored 202 publications, the most recent in 2026, and is an investigator in 10 clinical trials, 3 of them ongoing. SLR score: 724 (community average: 125). How the SLR is computed.

LeadR Profile

Frédéric Dumont Institut de Cancérologie de l'Ouest France
724 ScienceLeadR Reputation 724

Unlock

Register Login
Network Map

Surgery

Subspecialties: Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2005 - 2026
Source: PubMed

Institut de Cancérologie de l'Ouest

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 202

Citations

Citations: 7 025 1st author: 40 Last author: 5 Unique author: 0

Main journals

Ann Surg Oncol 25
Eur J Surg Oncol 21
Ann Surg 11
J Visc Surg 8
J Surg Oncol 6

Best Journals

J Clin Oncol 1
N Engl J Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Immune profile dysregulation of high grade- compared to low grade-pseudomyxomas.
PMID 42933311 — cells, genes, pseudomyxoma peritonei, pathology, immunity		Pathol Res Pract20260
Artificial-intelligence assistance for diagnosis, detection and surgical decision-making in colorectal peritoneal metastases: A cross-sectional BIG-RENAPE pilot study.
PMID 42580203 — pilot projects, pilots, intelligence, decision making, biopsy, neoplasm metastasis, diagnosis, therapeutics, medical oncology, artificial intelligence, surgeons		Eur J Surg Oncol20260
Improving surgical management of patients with extensive peritoneal metastases using damage control techniques.
PMID 42648157 — neoplasm metastasis, wounds and injuries		Surg Oncol20260
Comparison of surgical and oncological outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in upper and middle/lower rectal peritoneal metastases.
PMID 42648158 — cytoreduction surgical procedures, hyperthermia, induced, hyperthermic intraperitoneal chemotherapy, drug therapy, neoplasm metastasis, risk factors, chemotherapy		Surg Oncol20260
Methodological Pluralism in Surgical Evidence: from Concept to Practice.
PMID 42662508		Surg Pract Sci20260

Clinical Studies 10

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4

By phase:

N/A 6
Phase 2 2
Phase 1/Phase 2 1
Phase 2/Phase 3 1

By status:

Completed 4
Recruiting 2
Terminated 2
Not yet recruiting 1
Unknown 1

By type:

Interventional 7
Observational 3

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 3
multicentric5to9 1
multicentricup10 4

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Systemic antitumor treatment with or without pressurized intraperitoneal aerosol chemotherapy (PIPAC) for colon peritoneal metastases a multicentre phase II randomized trial (PIPOX02)
2024-514560-10-00 — aerosols, neoplasms, colon, drug therapy, neoplasm metastasis, therapeutics, chemotherapy, pressurized intraperitoneal aerosol chemotherapy		Phase 2Recruiting2025
Systemic Antitumor Treatment with or Without Pressurized Intraperitoneal Aerosol Chemotherapy for Colon Peritoneal Metastases (PIPOX02)
NCT06681038 — surgical oncology, vascular endothelial growth factor a, progression-free survival, aerosols, neoplasms, colon, drug therapy, oxaliplatin, neoplasm metastasis, therapeutics, colorectal neoplasms, chemotherapy, pressurized intraperitoneal aerosol chemotherapy		Phase 2Not yet recruiting2025
Study Evaluating the Tailored Management of Locally advanced Rectal Carcinoma
NCT04749108 — radiotherapy, intensity-modulated, radiotherapy, induction chemotherapy, radiologists, neoplasms, drug therapy, oxaliplatin, proctectomy, chemoradiotherapy, rectal neoplasms, morbidity, therapeutics, software, capecitabine, laparotomy, irinotecan, chemotherapy, carcinoma		Phase 2/Phase 3Recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS